Matching articles for "lisocabtagene maraleucel"
In Brief: Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • June 26, 2023; (Issue 1679)
The FDA has approved lisocabtagene maraleucel
(Breyanzi – BMS) for treatment of adults with large
B-cell lymphoma (LBCL), including diffuse large
B-cell lymphoma (DLBCL) not otherwise...
The FDA has approved lisocabtagene maraleucel
(Breyanzi – BMS) for treatment of adults with large
B-cell lymphoma (LBCL), including diffuse large
B-cell lymphoma (DLBCL) not otherwise specified,
high-grade B-cell lymphoma, primary mediastinal
large B-cell lymphoma, or follicular lymphoma
grade 3B who have disease refractory to first-line
chemoimmunotherapy, relapsed within 12 months
of or after first-line chemoimmunotherapy, are not
eligible for hematopoietic stem cell transplantation
due to comorbidities or age, or have relapsed
or refractory disease after ≥2 lines of systemic
therapy. Breyanzi is an individualized cellular
product prepared from the patient's own T cells,
which are genetically modified to express chimeric
antigen receptors (CAR) and then infused back into
the patient. The CAR T-cell products axicabtagene
ciloleucel (Yescarta) and tisagenlecleucel (Kymriah)
are also FDA-approved for treatment of large B-cell
lymphoma.